BridgeMD
A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination.
EU CTIS ID: 2024-515228-36-00
What this study is testing
The main objective of the study is to demonstrate the reduction in infective capacity of body fluids (cervical, anal, urine, vulvar and oral samples) in adult women at least HPV 16 and/or, 18 positive after vaccination with 9vHPV in a three-dose regimen
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Are women, aged 18 years or older for cohort 1 and cohort 2 , attending a routine cervical cancer screening visit or gynecological visit, are positive for HPV16 and/or HPV18 have been recently diagnosed for their HPV-positivity (within the last 10 months) and meet one of the following criteria: RIFT-HPV 1 cohort: non-vaccinated adult women aged 18 years or older, positive on cervix for HPV 16 and/or 18, with non apparent cervical lesion or with cervical lesion , eligible for conservative treatment. RIFT-HPV 2 cohort: non-vaccinated adult women aged 18 years or older, positive for HPV 16 and/or HPV 18 anal test with non-apparent anal lesions or with anal lesions eligible for conservative treatment. Or non-vaccinated adult women aged 18 years or older, positive for HPV 16 and/or HPV 18 cervical test with vulvar premalignant lesion or condylomas, associated to HPV infection.
- Are judged to have no major health conditions (based on medical history, physical examination, and laboratory testing) that may compromise their capacity to comply with study procedures, as per Investigator’s judgement.
- Provide written informed consent for their participation in the study.
- Provide a frequent contact telephone number as well as an alternate means of contact (such as an alternate telephone number or email) for follow-up purposes.
- Are planning to stay in their area of residence (near the study site) for the full duration of the study, so it is convenient for them to attend study visits at the site.
You likely can't join if
- Have any cervical lesion that requires clinical intervention within 7 months that could significantly affect cervical epithelia (and therefore, HPV viral production), such as cervical conization (RIFT-HPV Cohort 1).
- Are, at the time of signing informed consent, using recreational or illicit drugs or have had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the Investigator that might interfere with her capacity to comply with study procedures. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use.
- Have a fever (defined as temperature ≥37.8°C) within the 24-hour period prior to the Day 1 visit (Visit 1)*.
- Have a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
- Are allergic to any vaccine component, including aluminium, yeast, or BENZONASETM (nuclease, Nicomedia [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe adverse event (SAE), defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or results in persistent or significant disability/incapacity.
- Have known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection of study vaccine.
See the full eligibility criteria
Who can join
- Are women, aged 18 years or older for cohort 1 and cohort 2 , attending a routine cervical cancer screening visit or gynecological visit, are positive for HPV16 and/or HPV18 have been recently diagnosed for their HPV-positivity (within the last 10 months) and meet one of the following criteria: RIFT-HPV 1 cohort: non-vaccinated adult women aged 18 years or older, positive on cervix for HPV 16 and/or 18, with non apparent cervical lesion or with cervical lesion , eligible for conservative treatment. RIFT-HPV 2 cohort: non-vaccinated adult women aged 18 years or older, positive for HPV 16 and/or HPV 18 anal test with non-apparent anal lesions or with anal lesions eligible for conservative treatment. Or non-vaccinated adult women aged 18 years or older, positive for HPV 16 and/or HPV 18 cervical test with vulvar premalignant lesion or condylomas, associated to HPV infection.
- Are judged to have no major health conditions (based on medical history, physical examination, and laboratory testing) that may compromise their capacity to comply with study procedures, as per Investigator’s judgement.
- Provide written informed consent for their participation in the study.
- Provide a frequent contact telephone number as well as an alternate means of contact (such as an alternate telephone number or email) for follow-up purposes.
- Are planning to stay in their area of residence (near the study site) for the full duration of the study, so it is convenient for them to attend study visits at the site.
What rules you out
- Have any cervical lesion that requires clinical intervention within 7 months that could significantly affect cervical epithelia (and therefore, HPV viral production), such as cervical conization (RIFT-HPV Cohort 1).
- Are, at the time of signing informed consent, using recreational or illicit drugs or have had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the Investigator that might interfere with her capacity to comply with study procedures. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use.
- Have a fever (defined as temperature ≥37.8°C) within the 24-hour period prior to the Day 1 visit (Visit 1)*.
- Have a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
- Are allergic to any vaccine component, including aluminium, yeast, or BENZONASETM (nuclease, Nicomedia [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe adverse event (SAE), defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or results in persistent or significant disability/incapacity.
- Have known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection of study vaccine.
- Have a history of splenectomy.
- Have a history of ano-genital cancer or HPV-related head and neck cancer.
- Are pregnant at the time of signing informed consent, are planning to become pregnant within the full duration of the study.
- Have a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study or interfere with the subject’s compliance of study procedures for the full duration of the study, such that their inclusion in the study is not in the best interest of the subject and/or may compromise fulfilment of study’s objectives, by judgement of the Investigator.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.